An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
An Open-label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation.
Sponsor: Forest Laboratories
A PHASE4 clinical study on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation, this trial is completed. The trial is conducted by Forest Laboratories and has accumulated 10 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Jun 2018 — Sep 2019 [monthly]
Completed PHASE4
-
May 2018 — Jun 2018 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Apr 2018 — May 2018 [monthly]
Active Not Recruiting PHASE4
-
Feb 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Forest Laboratories
- Ironwood Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .